May 13, 2019 · Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in …

DCC-2618 is a pan-KIT and PDGFRα kinase switch control inhibitor resilient to de-novo and drug resistance mutations and its potency is independent of ATP concentration. Non-clinical data …

Ripretinib is the first new drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).

Updated results of phase 1 study of ripretinib (DCC-2618), a broad spectrum KIT and PDGFRA inhibitor, in patients with gastrointestinal stromal tumor (GIST) by line of therapy (NCT02571036).

Ripretinib is a novel, oral, potent pan-KIT and PDGFRα kinase inhibitor with activity across a broad range of mutations. These include primary KIT exons 9, 11, or 17 as well as secondary …

Dec 1, 2016 · • DCC-2618 is a KITand PDGFRA inhibitor resilient to gain-of-function and drug resistance mutations mutations – Potency independent of ATP concentration • DCC-2618 was …

Ripretinib (DCC-2618) suppresses phosphorylation of KIT and decreases the expression of phosphosphorylated (p)STAT5, pAKT and pERK1/2 in neoplastic mast cells. Ripretinib inhibits …

DCC-2618 is an orally active, potent type II switch pocket (SP) inhibitor against c-KIT (IC 50 = 4 nM/WT, 8 nM/V654A, 18 nM/T670I, 5 nM/D816H, 14 nM/D816V) and PDGFR. DCC-2618 …

In our current study, we show that DCC-2618 is a potent inhibitor of growth and survival of neoplastic human MC expressing various KIT mutations. Furthermore, we show that DCC …

Aug 17, 2021 · Qinlock ® (ripretinib, DCC-2618) is a type II switch control tyrosine kinase inhibitor (TKI) that inhibits a broad spectrum of oncogenic and drug-resistant variants of KIT and …